Inclusion of participants from low-income and middle-income countries in core outcome sets development: a systematic review.
epidemiology
protocols & guidelines
public health
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
19 10 2021
19 10 2021
Historique:
entrez:
20
10
2021
pubmed:
21
10
2021
medline:
4
11
2021
Statut:
epublish
Résumé
Our study aims to describe differences or similarities in the scope, participant characteristics and methods used in core outcome sets (COS) development when only participants from high-income countries (HICs) were involved compared with when participants from low-income and middle-income countries (LMICs) were also involved. Systematic review. Annual Core Outcome Measures in Effectiveness Trials systematic reviews of COS which are updated based on SCOPUS and MEDLINE, searches. The latest systematic review included studies published up to the end of 2019. We included studies reporting development of a COS for use in research regardless of age, health condition or setting. Studies reporting the development of a COS for patient-reported outcomes or adverse events or complications were also included. Data were extracted in relation to scope of the COS study, participant categories and the methods used in outcome selection. Studies describing 370 COS were identified in the database. Of these, 75 (20%) included participants from LMICs. Only four COS were initiated from an LMIC setting. More than half of COS with LMIC participants were developed in the last 5 years. Cancer and rheumatology were the dominant disease domains. Overall, over 259 (70%) of COS explicitly reported including clinical experts; this was higher where LMIC participants were also included 340 (92%). Most LMIC participants were from China, Brazil and South Africa. Mixed methods for consensus building were used across the two settings. Progress has been made in including LMIC participants in the development of COS, however, there is a need to explore how to enable initiation of COS development from a range of LMIC settings, how to ensure prioritisation of COS that better reflects the burden of disease in these contexts and how to improve public participation from LMICs.
Identifiants
pubmed: 34667005
pii: bmjopen-2021-049981
doi: 10.1136/bmjopen-2021-049981
pmc: PMC8527127
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e049981Subventions
Organisme : Medical Research Council
Pays : United Kingdom
Informations de copyright
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
PLoS One. 2018 Dec 28;13(12):e0209869
pubmed: 30592741
Am J Obstet Gynecol. 2019 Jan;220(1):71.e1-71.e4
pubmed: 30273584
Soc Sci Med. 2008 May;66(10):2076-87
pubmed: 18316147
Epilepsy Behav. 2018 Mar;80:56-60
pubmed: 29414559
PLoS One. 2019 Dec 12;14(12):e0225980
pubmed: 31830081
PLoS One. 2016 Jan 19;11(1):e0146444
pubmed: 26785121
Trials. 2007 Nov 26;8:39
pubmed: 18039365
Trials. 2017 Jun 20;18(Suppl 3):280
pubmed: 28681707
PLoS One. 2016 Dec 14;11(12):e0168403
pubmed: 27973622
J Health Serv Res Policy. 2012 Jan;17(1):1-2
pubmed: 22294719
Int J Lepr Other Mycobact Dis. 2005 Mar;73(1):13-21
pubmed: 15898834
J Clin Epidemiol. 2020 Sep;125:206-212.e1
pubmed: 31945480
Hum Reprod. 2014 Oct 10;29(10):2075-82
pubmed: 25217611
BMJ Open Diabetes Res Care. 2019 Dec 29;7(1):e000700
pubmed: 31908789
Trials. 2012 Aug 06;13:132
pubmed: 22867278
Cancer. 1981 Jan 1;47(1):207-14
pubmed: 7459811
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
PLoS Med. 2017 Nov 16;14(11):e1002447
pubmed: 29145404
PLoS One. 2019 Sep 13;14(9):e0222418
pubmed: 31518375
BMJ Paediatr Open. 2017 Aug 23;1(1):e000017
pubmed: 29637094
PLoS One. 2009 Jul 17;4(7):e6276
pubmed: 19609438
Arch Dis Child. 2015 Apr;100(4):359-63
pubmed: 25414251
PLoS Med. 2011 Jan 25;8(1):e1000393
pubmed: 21283604
J Clin Epidemiol. 2018 Oct;102:99-106
pubmed: 29966731
Vaccine. 2007 Jul 9;25(28):5115-23
pubmed: 17577487
BMJ Open. 2017 May 29;7(5):e015418
pubmed: 28554931
Res Involv Engagem. 2016 Jul 8;2:25
pubmed: 29507761
Trends Hear. 2018 Jan-Dec;22:2331216518814384
pubmed: 30488765
PLoS One. 2018 Feb 13;13(2):e0190695
pubmed: 29438429
J Clin Epidemiol. 2017 Jun;86:140-152
pubmed: 28495644
Obstet Gynecol. 2016 Jan;127(1):49-58
pubmed: 26646133
J Orthop Surg Res. 2019 Oct 9;14(1):317
pubmed: 31597557
JAMA Oncol. 2017 May 1;3(5):677-685
pubmed: 28033439
Trials. 2017 Mar 14;18(1):122
pubmed: 28288676
Lancet. 2009 Jul 4;374(9683):86-9
pubmed: 19525005
PLoS One. 2014 Jun 16;9(6):e99111
pubmed: 24932522
J Rheumatol. 1997 Nov;24(11):2225-9
pubmed: 9375888
BMJ Open. 2018 Apr 20;8(4):e021198
pubmed: 29678992
Lancet. 2020 Oct 17;396(10258):1204-1222
pubmed: 33069326
Arch Dis Child Fetal Neonatal Ed. 2020 Jul;105(4):425-431
pubmed: 31732683